Drugs.com - Clinical Trials

Research and Pipeline Research Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

NEW YORK--(BUSINESS WIRE)-- January 10, 2025 -- Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with...

Feb 9, 2025 - 21:44
 0
Research and Pipeline Research Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
NEW YORK--(BUSINESS WIRE)-- January 10, 2025 -- Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with...
Read More

Tags:

Previous Article

Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in...

Next Article

Nipocalimab Granted U.S. FDA Priority Review for the Treatment of Generalized My...

Related Posts

Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis

Amylyx Pharmaceuticals Announces FDA Has Lifted the Cli...

Feb 9, 2025  0

March Biosciences Receives FDA Orphan Drug Designation for MB-105, a First-in-Class CD5 CAR-T Cell Therapy, for T-Cell Lymphoma

March Biosciences Receives FDA Orphan Drug Designation ...

Feb 9, 2025  0

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

Eledon Pharmaceuticals Announces Use of Tegoprubart as ...

Feb 9, 2025  0